000170152 001__ 170152
000170152 005__ 20240229133706.0
000170152 0247_ $$2doi$$a10.1080/01635581.2021.1957133
000170152 0247_ $$2pmid$$apmid:34369225
000170152 0247_ $$2ISSN$$a0163-5581
000170152 0247_ $$2ISSN$$a1532-7914
000170152 0247_ $$2altmetric$$aaltmetric:111530897
000170152 037__ $$aDKFZ-2021-01782
000170152 041__ $$aEnglish
000170152 082__ $$a610
000170152 1001_ $$aStewart, Kelly L$$b0
000170152 245__ $$aAssociation of Sugar Intake with Inflammation- and Angiogenesis-Related Biomarkers in Newly Diagnosed Colorectal Cancer Patients.
000170152 260__ $$aNew York, NY$$bRoutledge, Taylor & Francis Group$$c2022
000170152 3367_ $$2DRIVER$$aarticle
000170152 3367_ $$2DataCite$$aOutput Types/Journal article
000170152 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1652441630_26049
000170152 3367_ $$2BibTeX$$aARTICLE
000170152 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000170152 3367_ $$00$$2EndNote$$aJournal Article
000170152 500__ $$a2022;74(5):1636-1643
000170152 520__ $$aEvidence suggests a positive association between sugar intake and colorectal cancer (CRC) outcomes. We sought to investigate inflammation and angiogenesis as underlying mechanisms behind increased sugar intake and worse CRC outcomes. Pre-surgery serum samples were obtained from 191 patients diagnosed with primary invasive stage I-IV CRC. Biomarkers of inflammation (CRP, SAA, IL-6, IL-8, MCP-1, TNFα) and angiogenesis (VEGFA, VEGFD, sICAM-1 and sVCAM-1) were analyzed (Meso-Scale-Discovery). Fructose, glucose, sucrose, and total sugar intake (calories/day, % total calories) were assessed by FFQ. Pearson's correlation and multiple linear regression analyses were performed. Patients were on average 64 years old, 64% were male, the majority was diagnosed with stage II-III (58%) cancers, and 67% were either overweight or obese. Among normal-weight individuals (BMI <25 kg/m2), we observed a significant inverse association between VEGFD and any type of sugar intake in cal/day (sucrose: p = 0.01, glucose and fructose: p < 0.001) and MCP-1 and fructose intake (p = 0.05). The magnitude of reduction in VEGF ranged between -1.24 for sucrose to 4.49 for glucose intake, and -2.64 for fructose intake for MCP-1 levels. Sugar intake was associated with some inflammation or angiogenesis biomarkers, among CRC patients; differences were observed by adiposity that warrant further investigation.Supplemental data for this article is available online at at 10.1080/01635581.2021.1957133.
000170152 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000170152 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000170152 7001_ $$aGigic, Biljana$$b1
000170152 7001_ $$aHimbert, Caroline$$b2
000170152 7001_ $$aWarby, Christy A$$b3
000170152 7001_ $$aOse, Jennifer$$b4
000170152 7001_ $$aLin, Tengda$$b5
000170152 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b6$$udkfz
000170152 7001_ $$aBoehm, Jürgen$$b7
000170152 7001_ $$00000-0002-0688-6514$$aJordan, Kristine C$$b8
000170152 7001_ $$00000-0003-4531-7725$$aMetos, Julie$$b9
000170152 7001_ $$aSchneider, Martin$$b10
000170152 7001_ $$aFigueiredo, Jane C$$b11
000170152 7001_ $$aLi, Christopher I$$b12
000170152 7001_ $$aShibata, David$$b13
000170152 7001_ $$aSiegel, Erin$$b14
000170152 7001_ $$aToriola, Adetunji T$$b15
000170152 7001_ $$aHardikar, Sheetal$$b16
000170152 7001_ $$aUlrich, Cornelia M$$b17
000170152 773__ $$0PERI:(DE-600)2025822-7$$a10.1080/01635581.2021.1957133$$gp. 1 - 8$$n5$$p1636-1643$$tNutrition and cancer$$v74$$x1532-7914$$y2022
000170152 909CO $$ooai:inrepo02.dkfz.de:170152$$pVDB
000170152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000170152 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000170152 9141_ $$y2021
000170152 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000170152 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000170152 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000170152 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNUTR CANCER : 2021$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-09
000170152 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-09
000170152 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000170152 980__ $$ajournal
000170152 980__ $$aVDB
000170152 980__ $$aI:(DE-He78)C120-20160331
000170152 980__ $$aUNRESTRICTED